The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.
CNSmedical
CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.
aldose reductase inhibitormedical
An aldose reductase inhibitor is a type of drug that blocks an enzyme which can convert excess sugar into forms that damage tissues, especially in complications of diabetes such as nerve, eye or kidney injury. Think of it like unclogging a drain to prevent harmful buildup; if the drug works, it can slow or prevent long-term damage. Investors care because successful inhibitors can address large unmet medical needs, drive drug sales, and hinge on clinical and regulatory milestones that affect company value.
classic galactosemiamedical
Classic galactosemia is a rare inherited disorder in which the body cannot properly break down galactose, a sugar found in milk, because a key processing enzyme is missing or faulty; untreated infants can become very sick within days. Investors care because the condition creates a clear need for lifelong management, diagnostic testing, newborn screening and potential treatments, making it a focused market for therapeutics, diagnostics and regulatory approval pathways.
A hereditary nerve disorder caused by loss of function in the sorbitol dehydrogenase enzyme, which normally helps clear a sugar alcohol called sorbitol from nerve cells; when the enzyme is missing or defective, sorbitol builds up and damages the long peripheral nerves that control sensation and movement. It matters to investors because it defines a specific, testable patient population and measurable biomarker (sorbitol levels), creating clearer paths for targeted drug development, clinical trials and potential regulatory approval or market opportunities—similar to fixing a clogged drain to prevent water damage.
PMM2-CDGmedical
PMM2‑CDG is a rare inherited metabolic disorder in which a basic cellular process that helps add sugar molecules to proteins goes wrong, causing a wide range of developmental, neurological and organ problems from infancy onward. Investors track it because there is high unmet medical need and limited treatment options, so successful therapies or diagnostic advances can create material commercial and regulatory opportunities as well as binary clinical trial and approval risks.
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--
Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company.
Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available.
“Cycle was founded with a commitment to support patients living with rare metabolic diseases. From our beginnings with NITYR®, we have grown to offer three therapies for this community. With Applied Therapeutics now a part of the Cycle group, we can look to expand further in this area. Our focus remains the same: to bring meaningful, reliable treatments to the patients and families who need them most.”says James Harrison, CEO of Cycle.
The transaction is to be funded from cash on hand.
For Cycle, Goodwin Procter LLP acted as legal counsel. For Applied, Aquilo Partners, L.P. provided a fairness opinion, and Ropes & Gray LLP acted as legal counsel.
Cycle was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease community. Cycle focuses on rare genetic conditions in metabolic, immunology, urology, and oncology. In neurology, we focus on multiple sclerosis. Cycle is headquartered in Cambridge, UK and has offices in Detroit, Michigan, Boston, Massachusetts and High Point, North Carolina. For more information, please visit www.cyclepharma.com and follow us on X, LinkedIn and Facebook.
